Pharmaceutical compositions for prevention or treatment of neurodegenerative diseases
AssigneesInserm (Institut National De La Santé Et La Recherche MéDicale), Universite Paul Sabatier Toulouse III, Centre National de la Recherche Scientifique (CNRS), Universite Pierre Et Marie Curie (Paris 6), Icm (Institut Du Cerveau Et De La Moelle éPinièRe)
InventorsDaniel DUNIA, Marion SZELECHOWSKI, Alexandre BETOURNE, Stephane HUNOT
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for the prevention or treatment of neurodegenerative diseases.
Claims12
A polypeptide comprising
- i) an amino acid sequence ranging from glycine at position 59 to alanine at position 85 in an amino acid sequence SEQ ID NO:1 or,
- ii) an amino acid sequence having at least 70% identity with the amino acid sequence ranging from glycine at position 59 to alanine at position 85 in the amino acid sequence SEQ ID NO:1,
- wherein the polypeptide is not the amino acid sequence SEQ ID NO:1;
- or
- a fusion protein comprising the polypeptide in which the polypeptide is fused to at least one heterologous polypeptide.
(canceled)
A nucleic acid sequence encoding
- I) a polypeptide comprising
- i) an amino acid sequence ranging from glycine at position 59 to alanine at position 85 in an amino acid sequence SEQ ID NO:1 or,
- ii) an amino acid sequence having at least 70% identity with the amino acid sequence ranging from glycine at position 59 to alanine at position 85 in the amino acid sequence SEQ ID NO:1,
- wherein the polypeptide is not the amino acid sequence SEQ ID NO:1;
- or
- II) a fusion protein comprising the polypeptide.
A vector comprising a nucleic acid sequence. encoding
- I) a polypeptide comprising
- i) an amino acid sequence ranging from glycine at position 59 to alanine at position 85 in an amino acid sequence SEQ ID NO:1 or,
- ii) an amino acid sequence having at least 70% identity with the amino acid sequence ranging from glycine at position 59 to alanine at position 85 in the amino acid sequence SEQ ID NO:1,
- wherein the polypeptide is not the amino acid sequence SEQ ID NO:1;
- or
- II) a fusion protein comprising the polypeptide.
A prokaryotic or eukaryotic host cell genetically transformed with at least one nucleic acid molecule encoding
- I) a polypeptide comprising
- i) an amino acid sequence ranging from glycine at position 59 to alanine at position 85 in an amino acid sequence SEQ ID NO:1 or,
- ii) an amino acid sequence having at least 70% identity with the amino acid sequence ranging from glycine at position 59 to alanine at position 85 in the amino acid sequence SEQ ID NO:1,
- wherein the polypeptide is not the amino acid sequence SEQ ID NO:1,
- II) a fusion protein comprising the polypeptide;
- or
- a vector comprising the nucleic acid.
A method for preventing or treating i) neurodegenerative disease, ii) neurodegenerative complications in a subject suffering from ischemia damage, or iii) mitochondrial disease in a subject in need thereof comprising
- administering to said subject
- I) a polypeptide comprising
- i) an amino acid sequence ranging from glycine at position 59 to alanine at position 85 in an amino acid sequence SEQ ID NO:1 or,
- ii) an amino acid sequence having at least 70% identity with the amino acid sequence ranging from glycine at position 59 to alanine at position 85 in the amino acid sequence SEQ ID NO:1,
- wherein the polypeptide is not the amino acid sequence SEQ ID NO:1;
- or
- II) a fusion protein comprising the polypeptide.
11-12. (canceled)
A pharmaceutical composition comprising
- I) a polypeptide comprising
- i) an amino acid sequence ranging from glycine at position 59 to alanine at position 85 in an amino acid sequence SEQ ID NO:1 or,
- ii) an amino acid sequence having at least 70% identity with the amino acid sequence ranging from glycine at position 59 to alanine at position 85 in the amino acid sequence SEQ ID NO:1,
- wherein the polypeptide is not the amino acid sequence SEQ ID NO:1;
- or
- II) a fusion protein comprising the polypeptide.
Dependencies are inferred from the claim text.